In men with high-grade prostate cancer, outcomes after radical prostatectomy are generally poorest for those with a low preoperative PSA (<2.5 ng/mL), according to a results of a study investigating disease-specific outcomes.
In men with high-grade prostate cancer, outcomes after radical prostatectomy are generally poorest for those with a low preoperative PSA (
Researchers from Northwestern University’s Feinberg School of Medicine, Chicago undertook a retrospective analysis that identified men who had undergone radical prostatectomy between 1983 and 2011 and who had a Gleason score of 8-10 in their prostatectomy specimen. A total of 354 patients met these criteria, and they were stratified into four groups based on their preoperative PSA:
Median duration of follow-up was 77 months, and 7-year outcomes were calculated for each PSA subgroup for biochemical progression-free survival, metastasis-free survival, and cancer-specific survival rates. For all three endpoints, men with a PSA
The 7-year metastasis-free survival rate for men with PSA
"These data should provide a wake-up call to physicians who might think there is no need to perform a biopsy in men whose PSA remains low or who might be less concerned about disease aggressiveness in a patient found to have a high-grade tumor but who has a low PSA level," said Dr. McGuire.
He added that the explanation for the paradoxical relationship between PSA level and tumor aggressiveness among men with Gleason 8-10 tumors lies in the knowledge that high-grade tumors that are very poorly differentiated can lose their ability to produce PSA.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.